Stock listing

Frankfurt:1RV Rhythm Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Rhythm Pharmaceuticals, Inc. · home listing NASDAQ:RYTM

Follow Rhythm Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:1RV

€80.00 EUR +3.00 (+3.9%)

Close on Oct 30, 2026

Day range
€80.00 – €81.50 EUROct 30, 2026
Market cap
€5.49B EURAt the close on Oct 30, 2026 · price × 68.59M shares outstanding
Rhythm Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RYTM · Home$93.44 USD+0.87 (+0.9%)1,946,040$93.13$95.06$93.04$92.57Close on Nov 2, 2026
Frankfurt:1RV€80.00 EUR+3.00 (+3.9%)—€81.50€81.50€80.00€77.00Close on Oct 30, 2026
Ticker
Frankfurt:1RV
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings Call

    Tue, Nov 03, 2026 · 8:00 AM ET

    Register

Replays

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 8:00 AM ET

    Watch Transcript

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 8:00 AM ET

    Watch Transcript

  • Rhythm Pharmaceuticals (NASDAQ:RYTM) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

Nov 2, 2026

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

Oct 21, 2026

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Oct 13, 2026

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Sep 22, 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Sep 10, 2026

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Aug 24, 2026

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Aug 17, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Aug 11, 2026

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 4, 2026

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Aug 4, 2026

All Rhythm Pharmaceuticals, Inc. news

Decks

Rhythm Pharmaceuticals, Inc. on 6ix

News releases
38 in the last 12 months · 222 in all · newest Nov 3, 2026 · oldest 2019
Calls
21 calls with a replay · 21 with a transcript · latest Aug 4, 2026
Decks
57 decks · latest September 2026

Where Rhythm Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RYTM · Home listingNASDAQUnited StatesUSD
LS Exchange:A2H5A0LS ExchangeGermanyEUR
Lang & Schwarz:A2H5A0Lang & SchwarzGermanyEUR
gettex:1RVgettexGermanyEUR
Tradegate:1RVTradegateGermanyEUR
BMV:RYTMBMVMexicoMXN
BOATS:RYTMBOATSUnited StatesUSD
Frankfurt:1RV · This pageFrankfurtGermanyEUR
BIVA:RYTMBIVAMexicoMXN
Dusseldorf:1RVDusseldorfGermanyEUR
Munich:1RVMunichGermanyEUR
Stuttgart:1RVStuttgartGermanyEUR
Xetra:1RVXetraGermanyEUR

Log in to ask 6ix AI your own questions about Rhythm Pharmaceuticals, Inc.